Webinar Home Page
Personalized Therapies and Best Clinical Practices for Lung Cancer 2018
January 1, 2018 – January 1, 2019
Click below to view
Dr. Bunn
Webinar #4233a
Re-evaluating options for 1st-line therapy of NSCLC patients with immune therapy with high-PD-L1 expression levels?
Dr. Bunn
Dr. Bunn
Webinar #4233b
Expert Panel Discussion and Audience Q & A
Dr. Bunn
Dr. Hirsch
Webinar #4233c
Mini-Presentation: Re-evaluating options for 1st-line NSCLC therapy using immune therapy for patients with low or no-PD-L1 expression?
Dr. Hirsch
Dr. Wakelee
Webinar #4233d
Salvage options for treating NSCLC patients who have progressed after initial systemic therapy: (immune therapy, chemotherapy, targeted therapy or any combinations).
Dr. Wakelee
Dr. Bunn
Webinar #4233e
Expert Panel Discussion and Audience Q & A
Dr. Bunn
Dr. West
Webinar #4233f
Mini-Presentation: When should immune therapy be used in patients with a prior immune-related adverse event (irAE toxicity) that has been resolved? or in patients who presently have an auto-immune disease such as ulcerative colitis, pancreatitis, hypophysitis, etc.?
Dr. West
Dr. West
Webinar #4233g
Mini-Presentation: : Is there a subset of NSCLC patients for whom consideration of using checkpoint inhibition should be a low priority?
Dr. West
Dr. Bunn
Webinar #4233h
Expert Panel Discussion and Audience Q & A
Dr. Bunn
Dr. Bunn Dr. Wakelee
Webinar #4233i
Mini-DEBATE: Immune therapy should be continued indefinitely in NSCLC patients after disease progression, especially after a long, durable response?
Yes (Dr. Bunn)
No (Dr. Wakelee)
Dr. Goldman
Webinar #4233j
Expert Panel Discussion and Q&A
Faculty
Dr. Curran
Webinar #4233k
New Advances Utilizing Radiation Therapy in Combination with Systemic Therapies for NSCLC
Dr. Curran
Dr. Wong
Webinar #4233l
Squamous Cell Cancer of the Head & Neck (SCCHN): Immune Therapy for patients with Disease Progression on or after Platinum-BASED THERAPY
Dr. Wong
Faculty
Webinar #4233m
Expert Panel Discussion and Audience Q & A
Faculty
Marianne Davies, DNP, AOCNP
Webinar #4233n
Improving Patient Outcomes in Lung Cancer Nursing Clinical Issues
Marianne Davies, DNP, AOCNP
Jim Koeller, MS
Webinar #4233o
A New Paradigm in Cancer Care Reimbursement: An Update on MACRA
Jim Koeller, MS
Dr. Ramalingam
Webinar #4233p
What are the clinical applications using chemotherapy for nonsquamous NSCLC in the era of immune therapy? In the up-front settings? In the salvage therapy settings?
Dr. Ramalingam
Dr. Bunn
Webinar #4233q
The new landscape for 1st-line squamous NSCLC: What is optimal therapy and what are the leading considerations for patients with low or no PD-L1 expression? What is optimal up-front therapy for squamous NSCLC patients with high PD-L1 expression?
Dr. Bunn
Faculty
Webinar #4233r
Expert Panel Discussion and Audience Q & A
Faculty
Dr. Ramalingam
Webinar #4233s
Current and Emerging NSCLC Molecular Targets: AND What are the clinical applications of current and evolving targeted therapies and standard chemotherapies for these NCSLC targets?
Dr. Ramalingam
Dr. Bunn
Webinar #4233t
Predicting to use immune therapy: Identifying who will benefit from the several available tests?
Dr. Bunn
Dr. Natale
Webinar #4233u
For Squamous NSCLC what are the clinical applications of anti-EGFR targeted and anti-VEGFR & therapies? How do they compare with the other FDA approved options? What about implications for NSCLC maintenance therapy?
Dr. Natale
Dr. Riely
Webinar #4233v
ALK-Rearrangement NSCLC: 1st Line Therapy Options: Should one of the following four targeted therapies be considered as THE 1st-line standard of care?
Dr. Riely
Dr. West
Webinar #4233w
Prioritizing therapeutic options post ALK-acquired resistance for 2nd-line and 3rd-line therapies for NSCLC patients. (chemotherapy, vs. further ALK-directed therapy, vs. immune therapy)
Dr. West
Faculty
Webinar #4233x
Expert Panel Discussion and Audience Q & A
Faculty
Dr. Borghaei
Webinar #4233y
EGFR NSCLC: 1st Line Therapy Options (1st, 2nd and 3rd-generation anti-EGFR agents)
Dr. Borghaei
Dr. Wakelee
Webinar #4233z
Prioritizing therapeutic options post EGFR-acquired resistance for 2nd-line and 3rd-line therapies for NSCLC patients.
Dr. Wakelee
Faculty
Webinar #4233aa
Expert Panel Discussion and Audience Q & A
Faculty